National Conference of the Italian Group for the Study of Neuromorphology
Vol. 70 No. s2 (2026): 36th National Conference of the Italian Group for the Study of...

P023 | GLOBAL DYSREGULATION OF THE SPECIALIZED PRO-RESOLVING MEDIATOR NETWORK IN PERIPHERAL MACROPHAGES OF PD PATIENTS WITH AND WITHOUT GBA1 MUTATIONS

G. Forte1|5, F. Leo2, E. Bianchini2|3, G. Vivacqua4, A. Leuti1|5, M. Marano2 | 1Department of Medicine and Surgery, Reserch Unit of Biochemistry, Campus Bio-Medico University of Roma, Italy; 2Parkinson's Disease and Movement Disorders Service, Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; 3Univ. Grenoble Alpes, CNRS, Grenoble INP, LIG Sangria, France; 4Department of Medicine and Surgery, Laboratory of Microscopic and Ultrastructural Anatomy, Campus Bio-Medico University of Roma, Italy; 5LIFE Institute for Research and Health Care - Santa Lucia IRCCS, Italy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 November 2026
0
Views
0
Downloads

Authors

Objectives. Neuroinflammation is a recognized pathological hallmark of Parkinson’s disease (PD). Heterozygous mutations in the GBA1 gene represent the most frequent genetic risk factor for PD. PD carriers of GBA1 mutations (GBA‐PD) progress more rapidly, with earlier cognitive dysfunction and psychosis, greater substantia nigra terminal loss, and reduced survival 1-2. While chronic activation of the innate immune system is well established in neurodegeneration, the mechanisms governing the "resolution of inflammation" – an active process driven by endogenous polyunsaturated lipids called Specialized Pro-resolving Mediators (SPMs) – remain largely unexplored in peripheral immune cells of PD patients3. Our aim, therefore, is to characterize the protein expression profiles of key SPM receptors (GPR18, GPR32, ChemR23, FPR2) and biosynthetic enzymes (15-PGDH, 15-LOX, 12-LOX, 5-LOX) in classically activated macrophages (M1-like) and alternatively activated macrophages (M2-like) across idiopathic PD, GBA-mutated PD and healthy controls.
Methods. Peripheral blood mononuclear cells were isolated from patients and monocytes were differentiated into macrophages M1- and M2-like. Target protein expression was quantified via flow cytometry using Mean Fluorescence Intensity (MFI). Group segregation and key driving biomarkers were identified using univariate statistics and multivariate Partial Least Squares-Discriminant Analysis (PLS-DA) with Variable Importance in Projection (VIP) scores. The phagocytic capacity of the macrophages in all experimental groups was assessed using the efferocytosis assay.
Results. Multivariate PLS-DA effectively separated the clinical groups from healthy controls, identifying 12-LOX, ChemR23 and 15-LOX as the top driving features. In macrophages M1-like, a significant downregulation of the pro-resolving receptor ChemR23 was observed in both PD and PD-GBA groups compared to controls, accompanied by an upregulated expression trend for the GPR32 receptor in idiopathic PD cases and a significant upregulation of the 12-LOX enzyme that was particularly pronounced in the PD-GBA cohort. At the same time, in M2-like macrophages, which are crucial for tissue repair and homeostasis, multivariate PLS-DA identifies ChemR23, FPR2, and the enzyme 5-LOX as the most significant discriminating biomarkers. In particular, there is a significant reduction in the expression of both pro-resolving receptors ChemR23 and FPR2 compared to controls, alongside a marked downregulation trend for GPR18 in sporadic PD. The efferocytosis assay revealed a reduced phagocytic capacity in PD macrophages compared with the controls.
Conclusions. Our results highlight a global alteration of the resolution of inflammation process in Parkinson’s disease. Particular attention centers on macrophages, the key players; which in both M1- and M2-like states, and across both idiopathic PD and PD-GBA groups, showed a dysregulated expression of SPM receptors and biosynthetic enzymes compared to healthy controls. This systemic imbalance may fail to counteract chronic inflammation, thereby contributing to neurodegeneration.

Downloads

Download data is not yet available.

Citations

1. Marano M et al., Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson’s disease, Parkinsonism and Related Disorders, 2024, 124, 107023.
2. Marano M et al., Association between plasma glucosylsphingosine levels and dyskinesia burden in GBA1-related Parkinson's disease, Neurobiology of Disease, 2026, 219, 107271.
3. Leuti A et al., Bioactive lipids, inflammation and chronic diseases, Advanced Drug Delivery Reviews, 2020, 159:133-169.

How to Cite



1.
P023 | GLOBAL DYSREGULATION OF THE SPECIALIZED PRO-RESOLVING MEDIATOR NETWORK IN PERIPHERAL MACROPHAGES OF PD PATIENTS WITH AND WITHOUT GBA1 MUTATIONS: G. Forte1|5, F. Leo2, E. Bianchini2|3, G. Vivacqua4, A. Leuti1|5, M. Marano2 | 1Department of Medicine and Surgery, Reserch Unit of Biochemistry, Campus Bio-Medico University of Roma, Italy; 2Parkinson’s Disease and Movement Disorders Service, Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; 3Univ. Grenoble Alpes, CNRS, Grenoble INP, LIG Sangria, France; 4Department of Medicine and Surgery, Laboratory of Microscopic and Ultrastructural Anatomy, Campus Bio-Medico University of Roma, Italy; 5LIFE Institute for Research and Health Care - Santa Lucia IRCCS, Italy. Eur J Histochem [Internet]. 2026 Nov. 20 [cited 2026 Nov. 20];70(s2). Available from: https://www.ejh.it/ejh/article/view/4843